|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019046,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0205251,
umls-concept:C0332282,
umls-concept:C0332293,
umls-concept:C0357126,
umls-concept:C0596545,
umls-concept:C0936012,
umls-concept:C1442488,
umls-concept:C1549003,
umls-concept:C1879316
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-1-10
|
|
pubmed:abstractText |
The introduction of recombinant human erythropoietin to the management of anemia in cancer patients has resulted in significant reductions in allogeneic blood transfusions, while at the same time contributing to improvements in quality of life. A recent meta-analysis of five randomized, placebo-controlled trials with patient-level data revealed that, while epoetin alfa was very effective in reducing transfusions compared with placebo, patients who were pretransfused were twice as likely to subsequently be transfused during epoetin alfa treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1083-7159
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
73-82
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16401716-Adolescent,
pubmed-meshheading:16401716-Adult,
pubmed-meshheading:16401716-Aged,
pubmed-meshheading:16401716-Aged, 80 and over,
pubmed-meshheading:16401716-Anemia,
pubmed-meshheading:16401716-Canada,
pubmed-meshheading:16401716-Erythrocyte Transfusion,
pubmed-meshheading:16401716-Erythropoietin,
pubmed-meshheading:16401716-Female,
pubmed-meshheading:16401716-Hematinics,
pubmed-meshheading:16401716-Hemoglobins,
pubmed-meshheading:16401716-Humans,
pubmed-meshheading:16401716-Linear Models,
pubmed-meshheading:16401716-Male,
pubmed-meshheading:16401716-Middle Aged,
pubmed-meshheading:16401716-Multivariate Analysis,
pubmed-meshheading:16401716-Neoplasms,
pubmed-meshheading:16401716-Recombinant Proteins,
pubmed-meshheading:16401716-Risk,
pubmed-meshheading:16401716-Risk Factors,
pubmed-meshheading:16401716-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
|
|
pubmed:affiliation |
Princess Margaret Hospital, Toronto, Ontario, Canada MG5 ZM9. ian.quirt@uhn.on.ca
|
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis,
Validation Studies
|
